Behind Canada’s current COVID-19 vaccine shortage is a decades-long tale of unheeded warnings, missed opportunities and dismantled resources that was never going to end well.
Academic rigour, journalistic flair
Articles on Moderna
Displaying 41 - 60 of 66 articles
With slow vaccine distribution and manufacturing, some people won’t get the second dose on time. But does it matter?
Historically, we immunized children against diseases like polio that were a clear danger to them, but COVID-19 is usually mild in children. However, herd immunity is unlikely without vaccinating kids.
Rollout of COVID-19 vaccines has begun. But getting the jab doesn’t mean abandoning masks, distancing and handwashing. Here’s why the current preventive measures must continue post-vaccine.
Many countries cannot afford to buy existing COVID-19 vaccines, a collective approach is needed.
With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it’s better to give one dose to more people and give a second when the supply is better.
Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
So far, the only COVID-19 vaccines authorized for use need to be kept frozen. But there are many places in the world that can’t support a cold supply chain.
With vaccines forthcoming for most Americans, many groups, including expectant mothers, are wondering if the vaccine is safe for them and their babies. A physician-scientist explains.
COVID-19 vaccines have very specific storage requirements that make shipping a difficult task. Two ideas – fulfillment centers and cross-docking – could help overcome some distribution challenges.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Millions of Americans say they won’t get the vaccine. Will money change their minds? And is luring them with cash the right approach?
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
The side effects of new SARS-CoV-2 vaccines are a result of immune system activation. While uncomfortable, they are both normal and expected. They are a sign that the vaccine is working.
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand’s.
Moderna’s shot is far easier to store and distribute than Pfizer’s. But there are concerns neither vaccine performs particularly well for older people.
The recent vaccine trial results certainly look impressive, but here’s how to fully interrogate what they mean.
Top contributors
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Medicine, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Assistant Professor, School of Professional Communication, Toronto Metropolitan University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Law, Villanova School of Law
-
Professorial Fellow, University of Canberra
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Associate Professor of Bioethics, University of Portsmouth
-
Associate Professor of Epidemiology, University of San Francisco
-
Professor of Epidemiology, Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne
